MedTrace Logo

Placebo-Controlled Pilot Trial of Mecamylamine for Treatment of Autism Spectrum Disorders

NCT00773812 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-01-13

No results posted yet for this study

Summary

The purpose of this study is to examine the safety and efficacy of mecamylamine for the core symptoms of autism.

Conditions

  • Autistic Disorder
  • Pervasive Developmental Disorder

Interventions

DRUG

mecamylamine

The dosage is titrated at 6 weeks of .5mg, 2 weeks of 2.5 mg, and 6 weeks of 5.0 mg. One pill is taken once daily.

DRUG

placebo

One pill is taken once daily.

Sponsors & Collaborators

  • Autism Speaks

    collaborator OTHER

  • Ohio State University

    lead OTHER

Principal Investigators

  • L E Arnold, M.D. · Ohio State University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
4 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2012-11-30
Completion
2012-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00773812 on ClinicalTrials.gov